Redecol are developing an asthma monitoring device to address the need for a new type of lung function test.

Redecol completed its funding round in September 2017, raising £555,437.50.

The story

Asthma is a common chronic respiratory problem, representing a serious health concern affecting approximately 300 million people around the world – a figure predicted to grow to 400 million by 2025. In the UK alone, 5.4 million people are affected by asthma and, on average, three people a day die from the disease. The European Asthma Research Innovation Partnership claims that over a period of eight years, 4 million asthma sufferers will be hospitalised and 120,000 will die.

Patient home monitoring of asthma is a problem space, with only 5% of asthmatics monitoring their condition effectively at home. Current monitoring methods, such as peak flow meters, require asthmatics to use a ‘forced’ breathing technique (forcefully emptying the lungs of air). Given that asthma is a respiratory disease, this can be exceedingly uncomfortable for sufferers (especially children and elderly people, who may be frailer than average).

It is estimated that asthma leads to a direct cost to the NHS of £1.1bn and a considerable indirect cost to society, due to time off work and loss of productivity. Home monitoring of asthma could therefore be a considerable cost saver.

Redecol wants to save lives via the deployment of their Breathe EasyFlow product, a home monitoring device that enables asthma sufferers to accurately take readings of their breathing capacity and status without undue forceful breathing. The company is also developing an app in tandem which will facilitate medical professionals’ home monitoring of patients, and track patient history.

Redecol’s Breathe EasyFlow

The Breathe EasyFlow analyses lung function and the severity of asthma symptoms, monitors results over time and provides an easy, app-based channel of communication between patient and doctor – without a reliance on forced breathing.

The Redecol breath sensor used in the device tracks deep, controlled breaths to create a breath profile shape which is then recorded and analysed, leading to improved asthma management and control.

This method also hopes to avoid undue hospital visitations, which can be time consuming, stressful and costly – according to the Asthma UK Centre in Applied Research, GP consultations for asthma currently cost the UK £160m per year.

The device is paired with Redecol’s cloud solution and app, intended to enable both sufferers and healthcare professionals to monitor the patient’s condition, allowing for corrective actions to be taken to minimise risk and monitor trends in the patient’s condition.

CEO Tim Coutts brings over 20 years’ experience in the medtech industry from multinational companies, such as Boston Scientific to SMEs, and is a former board member of ABHI.

The lead investor

Barbara Lead is CEO of Oval Medical, a specialty pharmaceuticals company based in Cambridge which was acquired by SMC Ltd last year. She has spent her career in pharma, having held VP positions in drug development and marketing. She has worked in the asthma and allergy therapy areas, including working with many international clinical opinion leaders in the development and marketing of asthma medication. In addition to her medical career, she is an experienced investor having invested in a number of startups.

I am excited about this opportunity, the product has the potential to really make a difference to patients. Since childhood asthma is increasing in the developed world the market will only continue to grow and there are many different commercial models that can be applied in different markets to maximise future sales.

Barbara Lead

Redecol lead investor

What investors say

‘Redecol have a brilliant technology that assesses lung function; I have invested in this technology for some years. Whilst the other applications of the core sensor have great potential, the take up has been slow. Its application in Asthma monitoring meets a very immediate need. This was highlighted by Asthma UK in their report.

The team have made impressive progress in their plan to commercialise this application, which should be of tremendous benefit to asthma suffers. I expect this to be one of my best life science investments.’

– Henry P, investor

See current opportunities

Articheck

EIS
Software & Computer Services
Articheck is an SaaS company which create passports for works-of-art to accompany them on their travels. The company raised funds on SyndicateRoom in 2017.

Active

Trading status

£12,624

Average investment

£618,571

Total raised

Brytlyt

EIS
Software & Computer Services
Brytlyt, a company creating a radically new approach to the underlying hardware for data processing, twice raised capital on SyndicateRoom. Read more here.

Active

Trading status

£9,961

Average investment

£473,400

Total raised

Biotechspert

EIS
Healthcare
Biotechspert aims to facilitate access to world-leading technical, scientific and commercial expertise. The company raised finance on SyndicateRoom.

Active

Trading status

£7,147

Average investment

£236,099

Total raised

Dymag

EIS
Engineering & Manufacturing
Dymag has twice raised funds on SyndicateRoom. The company designs and manufactures high-performance carbon composite car and motorcycle wheels.

Active

Trading status

£13,513

Average investment

£499,998

Total raised

Re-Vana Therapeutics

EIS
Pharmaceuticals & Biotechnology
Re-Vana Therapeutics is a life science spin-out from Queen’s University Belfast. The company raised £1,104,593 on SyndicateRoom in September 2017.

Active

Trading status

£19,725

Average investment

£1,104,593

Total raised

e-Patient Network

EIS
Healthcare
ePatient Network provides rare disease patients with up-to-date scientific information, community insights and medical research and connects them with clinical trial opportunities through its Raremark platform.

Active

Trading status

£12,087

Average investment

£470,374

Total raised